Literature DB >> 23472737

Further evaluation of a claims-based algorithm to determine the effectiveness of biologics for rheumatoid arthritis using commercial claims data.

Jeffrey R Curtis, Benjamin Chastek, Laura Becker, David J Harrison, David Collier, Huifeng Yun, George J Joseph.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23472737      PMCID： PMC3672715          DOI： 10.1186/ar4161

Source DB:  PubMed          Journal:  Arthritis Res Ther        ISSN： 1478-6354            Impact factor:   5.156


× No keyword cloud information.
  2 in total

1.  Use of administrative claims data for comparative effectiveness research of rheumatoid arthritis treatments.

Authors:  Seo Young Kim; Daniel H Solomon
Journal:  Arthritis Res Ther       Date:  2011-10-07       Impact factor: 5.156

2.  Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis.

Authors:  Jeffrey R Curtis; John W Baddley; Shuo Yang; Nivedita Patkar; Lang Chen; Elizabeth Delzell; Ted R Mikuls; Kenneth G Saag; Jasvinder Singh; Monika Safford; Grant W Cannon
Journal:  Arthritis Res Ther       Date:  2011-09-20       Impact factor: 5.156
  2 in total
  7 in total

Review 1.  Comparative effectiveness research with administrative health data in rheumatoid arthritis.

Authors:  Marie Hudson; Koray Tascilar; Samy Suissa
Journal:  Nat Rev Rheumatol       Date:  2016-04-15       Impact factor: 20.543

2.  The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare population.

Authors:  Huifeng Yun; Fenglong Xie; Elizabeth Delzell; Lang Chen; Shuo Yang; Kenneth G Saag; George Joseph; David Harrison; Jeffrey R Curtis
Journal:  Br J Clin Pharmacol       Date:  2015-09-30       Impact factor: 4.335

3.  Tumor Necrosis Factor Inhibitor Therapy and the Risk for Depression Among Working-Age Adults with Rheumatoid Arthritis.

Authors:  Arijita Deb; Nilanjana Dwibedi; Traci LeMasters; Jo Ann Hornsby; Wenhui Wei; Usha Sambamoorthi
Journal:  Am Health Drug Benefits       Date:  2019-02

4.  Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy.

Authors:  Machaon M K Bonafede; Donna McMorrow; Clare Proudfoot; Shraddha Shinde; Andreas Kuznik; Chieh-I Chen
Journal:  Am Health Drug Benefits       Date:  2018-06

5.  Application of a validated algorithm to estimate the effectiveness and cost of biologics for rheumatoid arthritis in the US pharmacy benefit manager context.

Authors:  Ning Wu; Sharvari Bhurke; Neel Shah; David J Harrison
Journal:  Clinicoecon Outcomes Res       Date:  2015-05-13

6.  Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication.

Authors:  Machaon Mk Bonafede; Jeffrey R Curtis; Donna McMorrow; Puneet Mahajan; Chieh-I Chen
Journal:  Clinicoecon Outcomes Res       Date:  2016-12-02

7.  Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis.

Authors:  Michael Grabner; Natalie N Boytsov; Qing Huang; Xiang Zhang; Tingjian Yan; Jeffrey R Curtis
Journal:  Arthritis Res Ther       Date:  2017-05-15       Impact factor: 5.156
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.